Emtricitabine/tenofovir
Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.
| Combination of | |
|---|---|
| Emtricitabine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide analogue reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Truvada, Tenvir-EM, other |
| Other names | Emtricitabine/tenofovir disoproxil fumarate |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a612036 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| NIAID ChemDB | |
| (verify) | |
Common side effects include headache, tiredness, trouble sleeping, abdominal pain, weight loss, and rash. Serious side effects may include high blood lactate levels and enlargement of the liver. Use of this medication during pregnancy does not appear to harm the fetus, but this has not been well studied.
Emtricitabine/tenofovir was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines. In the United States, emtricitabine/tenofovir was under patent by Gilead until 2020, but is now available as a generic worldwide. In 2020, it was the 278th most commonly prescribed medication in the United States, with more than 1 million prescriptions.